Skip to Content

Draft of: The Role of CSF in Alzheimer’s Disease

Expires: June 24, 2022

Presentation

View the Archived Webinar


Video length: 1 hour 1 minutes

Overview

Cerebrospinal fluid (CSF) has been used in research on Alzheimer’s disease for decades, but only recently have the platforms been developed to standardize measurements across laboratories. CSF data from the Mayo Clinic Study of Aging and the Mayo Clinic Alzheimer’s Disease Research Center have been analyzed on the Roche Elecsys platform and will be discussed in the context of aiding in the diagnosis of Alzheimer’s disease.

Presenter

Ronald Petersen, M.D., Ph.D.
Professor of Neurology
Mayo Clinic, Rochester, Minnesota

Learning Objectives

Upon completion of this activity, participants should be able to:

  • List the criteria for diagnosing Alzheimer’s disease.
  • Discuss the validation of CSF markers for Alzheimer’s disease.
  • Identify the limitations of CSF testing for Alzheimer’s disease.

Intended Audience

This webinar is designed for any provider who sees patients with neurologic diseases (e.g., neurologists, psychiatrists, and primary care physicians, including internists and family care practitioners) as well as pathologists, laboratory directors, and laboratory send-out coordinators.

Credit

The following types of credit are offered for this event:
ASCLS P.A.C.E.®

Level of instruction for this program is intermediate.

To obtain credit:

  1. Watch the video.
  2. Complete the evaluation that will be sent to you after the program.
  3. Generate and print your certificate(s).

ASCLS P.A.C.E.®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Additional Resources

Questions?

Contact us: mcleducation@mayo.edu

Andrea Kelley

Andrea Kelley